Intellia Therapeutics (NTLA) Preferred Stock Liabilities (2015 - 2016)
Intellia Therapeutics (NTLA) posted quarterly Preferred Stock Liabilities of $88.6 million for Q1 2016, little changed quarter-over-quarter from $88.6 million in Q4 2015.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Preferred Stock Liabilities for 2 consecutive years, with $88.6 million the latest figure, recorded in Q1 2016.
- In Q1 2016, Preferred Stock Liabilities changed N/A year-over-year to $88.6 million; the TTM figure through Mar 2016 stood at $88.6 million (changed N/A YoY), while the FY2015 annual figure was $88.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $88.6 million in Q1 2016 per NTLA's latest filing, from $88.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $88.6 million in Q1 2016 and bottomed at $88.6 million in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | - |